1. Home
  2. AIN vs EWTX Comparison

AIN vs EWTX Comparison

Compare AIN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$50.31

Market Cap

1.5B

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$21.19

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIN
EWTX
Founded
1895
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
2.5B
IPO Year
1987
2021

Fundamental Metrics

Financial Performance
Metric
AIN
EWTX
Price
$50.31
$21.19
Analyst Decision
Hold
Buy
Analyst Count
4
9
Target Price
$64.25
$35.89
AVG Volume (30 Days)
427.4K
1.3M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
2.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,148,512,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.15
$10.60
52 Week High
$83.65
$33.38

Technical Indicators

Market Signals
Indicator
AIN
EWTX
Relative Strength Index (RSI) 51.55 43.20
Support Level $49.70 $22.77
Resistance Level $53.88 $25.00
Average True Range (ATR) 1.53 1.44
MACD 0.45 -0.51
Stochastic Oscillator 49.73 16.89

Price Performance

Historical Comparison
AIN
EWTX

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: